Matriks Biotek® is committed to research and development in addition to advancing product innovation at every turn. As a result of these; Our products on the market are consistently increasing. We have recently completed 3 new products for screening total anti-drug antibody to infliximab (Remicade), infliximab biosimilar CT-P13 (Remsima/Inflektra) and adalimumab (Humira); SHIKARI Q-ATI Total, SHIKARI S-AIR Total and S-ATA Total respectively and will be launched on coming days.
Visit our website for information about all of our products www.matriksbiotek.com
Ask information from email@example.com or a quote from firstname.lastname@example.org
Specifications of the tests: